Objective(s): Despite several proposed mechanisms for the pathophysiology of cardiorenal syndrome (CRS), the exact mechanism remains unclear. Nitrosative stress has been argued as a key mechanism recently. Nebivolol is a beta-blocker with nitric oxide (NO)-releasing effect. In the present study, NO-mediated effects of two different treatment regimes of nebivolol in CRS were studied
Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct vasodila...
The therapeutic effects of nonspecific beta-blockers are limited by vasoconstriction, thus justifyin...
Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing propert...
Endothelial dysfunction is major pathophysiologic mechanism in cardiac syndrome X (CSX), which cause...
Nebivolol is a β1-adrenergic receptor antagonist that also reduces blood pressure by evoking endothe...
Nebivolol is a beta1-adrenergic receptor antagonist that also reduces blood pressure by evoking endo...
The third generation beta-blockers possess important ancillary properties besides inhibiting beta-ad...
β-blockers are among the most widely used drugs in the prevention and treatment of cardiovascular di...
Background-Nebivolol is a beta-selective adrenergic receptor antagonist with proposed nitric oxide (...
Aim: During reperfusion of myocardial ischemia, damage can also be seen in the kidneys. Although man...
BACKGROUND: Nebivolol is a selective beta(1)-adrenergic receptor antagonist that causes a direct vas...
Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct vasodila...
<div><p>Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has b...
A highly complex interplay exists between the heart and kidney in the setting of both normal and abn...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct vasodila...
The therapeutic effects of nonspecific beta-blockers are limited by vasoconstriction, thus justifyin...
Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing propert...
Endothelial dysfunction is major pathophysiologic mechanism in cardiac syndrome X (CSX), which cause...
Nebivolol is a β1-adrenergic receptor antagonist that also reduces blood pressure by evoking endothe...
Nebivolol is a beta1-adrenergic receptor antagonist that also reduces blood pressure by evoking endo...
The third generation beta-blockers possess important ancillary properties besides inhibiting beta-ad...
β-blockers are among the most widely used drugs in the prevention and treatment of cardiovascular di...
Background-Nebivolol is a beta-selective adrenergic receptor antagonist with proposed nitric oxide (...
Aim: During reperfusion of myocardial ischemia, damage can also be seen in the kidneys. Although man...
BACKGROUND: Nebivolol is a selective beta(1)-adrenergic receptor antagonist that causes a direct vas...
Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct vasodila...
<div><p>Nebivolol, third-generation β-blocker, may activate β3-adrenergic receptor (AR), which has b...
A highly complex interplay exists between the heart and kidney in the setting of both normal and abn...
The importance of chronic stimulation of β-adrenoceptors in the development of cardiac dysfunction i...
Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct vasodila...
The therapeutic effects of nonspecific beta-blockers are limited by vasoconstriction, thus justifyin...
Nebivolol is a new selective beta 1-adrenoceptor antagonist with nitric oxide (NO)–releasing propert...
DOI
Add to ORKG